EZH2 and neoplasm: Alterations in EZH2 are predominately frameshift mutations resulting in truncated protein isoforms or missense mutations within the highly conserved methyltransferase domain, suggesting a tumor suppressor function of EZH2. Patients with MF harboring EZH2 abnormalities have a reduced leukemia-free and overall survival (OS) that is independent of the dynamic international prognostic scoring system (DIPSS) risk category and JAK2V617F allele burden26.